A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
Trial ID or NCT#
NCT02401048
Status
NOT RECRUITING
Purpose
The purpose of this study is to evaluate the efficacy, safety and tolerability of the combination treatment of ibrutinib and MEDI4736 in subjects with relapsed or refractory lymphomas.
Official Title
A Multi-Center Open-Label Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With MEDI4736, in Subjects With Relapsed or Refractory Lymphomas
Investigator(s)
Michael Khodadoust
Lymphoma specialist,
Cutaneous oncology specialist,
Hematologist,
Hematologist-Oncologist
Assistant Professor of Medicine (Oncology) and of Dermatology
Lauren Maeda
Hematologist,
Lymphoma specialist,
Hematologist-Oncologist
Clinical Associate Professor, Medicine - Oncology
Ash A. Alizadeh, MD/PhD
Medical oncologist,
Lymphoma specialist,
Cancer geneticist
Moghadam Family Professor
Sunil Arani Reddy
Medical oncologist,
Cutaneous oncology specialist
Clinical Associate Professor, Medicine - Oncology
Ronald Levy
Medical oncologist,
Lymphoma specialist
Robert K. and Helen K. Summy Professor in the School of Medicine
Contact us to find out if this trial is right for you.
Contact
Ami Okada
650-725-4968
View on ClinicalTrials.gov
